http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 20 Jul 2026 07:02:36 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/BioLineRx+and+Hemispherian+to+present+GLIX1+ovarian+cancer+data+at+ESMO/26786873.html <p>BioLineRx Ltd. (NASDAQ: BLRX) and Hemispherian AS announced that an abstract featuring pre-clinical data on GLIX1 in combination with PARP inhibitors has been accepted as an e-Poster at the 2026 European Society for Medical Oncology Annual Congress (ESMO 2026), scheduled for October 23–27 in Madrid, Spain.</p><p>The presentation, titled "GLIX1, a TET2 Activator Targeting the DNA Damage Response, Synergizes with PARP Inhibitors in Ovarian Cancer Cell Lines," will appear in the e-Poster Area, Hall 25, under presentation number 1435eP. The data focuses on pre-clinical findings in HR-proficient ovarian cancer cell lines.</p><p>GLIX1 is an orally administered small molecule that activates the TET2 http://www.streetinsider.com/Corporate+News/BioLineRx+and+Hemispherian+to+present+GLIX1+ovarian+cancer+data+at+ESMO/26786873.html Mon, 20 Jul 2026 07:02:36 -0400 BLRX http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+AS+to+Present+Data+Demonstrating+Strong+Synergy+of+GLIX1+with+PARP+Inhibitors+in+HR-Proficient+Ovarian+Cancers+at+ESMO+2026/26786816.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and <span value="ACORN:5021694850" idsrc="xmltag.org" >Hemispherian AS</span>, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that an abstract featuring pre-clinical data demonstrating strong synergy between GLIX1 and various PARP inhibitors in HR-proficient ovarian cancer cell lines has been accepted as an e-Poster at the 2026 European Society for Medical Oncology Annual Congress (ESMO 2026), taking place <chron>October http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+AS+to+Present+Data+Demonstrating+Strong+Synergy+of+GLIX1+with+PARP+Inhibitors+in+HR-Proficient+Ovarian+Cancers+at+ESMO+2026/26786816.html Mon, 20 Jul 2026 07:00:00 -0400 A.50216948 BLRX BLRX O.05892620 O.48070986 http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+AS+to+Present+Data+Demonstrating+Strong+Synergy+of+GLIX1+with+PARP+Inhibitors+in+HR-Proficient+Ovarian+Cancers+at+ESMO+2026/26786816.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and <span value="ACORN:5021694850" idsrc="xmltag.org" >Hemispherian AS</span>, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that an abstract featuring pre-clinical data demonstrating strong synergy between GLIX1 and various PARP inhibitors in HR-proficient ovarian cancer cell lines has been accepted as an e-Poster at the 2026 European Society for Medical Oncology Annual Congress (ESMO 2026), taking place <chron>October http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+AS+to+Present+Data+Demonstrating+Strong+Synergy+of+GLIX1+with+PARP+Inhibitors+in+HR-Proficient+Ovarian+Cancers+at+ESMO+2026/26786816.html Mon, 20 Jul 2026 07:00:00 -0400 A.50216948 BLRX BLRX O.05892620 O.48070986 http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+AS+to+Present+Data+Demonstrating+Strong+Synergy+of+GLIX1+with+PARP+Inhibitors+in+HR-Proficient+Ovarian+Cancers+at+ESMO+2026/26786816.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and <span value="ACORN:5021694850" idsrc="xmltag.org" >Hemispherian AS</span>, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that an abstract featuring pre-clinical data demonstrating strong synergy between GLIX1 and various PARP inhibitors in HR-proficient ovarian cancer cell lines has been accepted as an e-Poster at the 2026 European Society for Medical Oncology Annual Congress (ESMO 2026), taking place <chron>October http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+AS+to+Present+Data+Demonstrating+Strong+Synergy+of+GLIX1+with+PARP+Inhibitors+in+HR-Proficient+Ovarian+Cancers+at+ESMO+2026/26786816.html Mon, 20 Jul 2026 07:00:00 -0400 A.50216948 BLRX BLRX O.05892620 O.48070986 http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+AS+to+Present+Data+Demonstrating+Strong+Synergy+of+GLIX1+with+PARP+Inhibitors+in+HR-Proficient+Ovarian+Cancers+at+ESMO+2026/26786816.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and <span value="ACORN:5021694850" idsrc="xmltag.org" >Hemispherian AS</span>, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that an abstract featuring pre-clinical data demonstrating strong synergy between GLIX1 and various PARP inhibitors in HR-proficient ovarian cancer cell lines has been accepted as an e-Poster at the 2026 European Society for Medical Oncology Annual Congress (ESMO 2026), taking place <chron>October http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+AS+to+Present+Data+Demonstrating+Strong+Synergy+of+GLIX1+with+PARP+Inhibitors+in+HR-Proficient+Ovarian+Cancers+at+ESMO+2026/26786816.html Mon, 20 Jul 2026 07:00:00 -0400 A.50216948 BLRX BLRX O.05892620 O.48070986 http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+AS+to+Present+Data+Demonstrating+Strong+Synergy+of+GLIX1+with+PARP+Inhibitors+in+HR-Proficient+Ovarian+Cancers+at+ESMO+2026/26786816.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and <span value="ACORN:5021694850" idsrc="xmltag.org" >Hemispherian AS</span>, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that an abstract featuring pre-clinical data demonstrating strong synergy between GLIX1 and various PARP inhibitors in HR-proficient ovarian cancer cell lines has been accepted as an e-Poster at the 2026 European Society for Medical Oncology Annual Congress (ESMO 2026), taking place <chron>October http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+AS+to+Present+Data+Demonstrating+Strong+Synergy+of+GLIX1+with+PARP+Inhibitors+in+HR-Proficient+Ovarian+Cancers+at+ESMO+2026/26786816.html Mon, 20 Jul 2026 07:00:00 -0400 A.50216948 BLRX BLRX O.05892620 O.48070986 http://www.streetinsider.com/PRNewswire/BioLineRx+and+Hemispherian+AS+to+Present+Data+Demonstrating+Strong+Synergy+of+GLIX1+with+PARP+Inhibitors+in+HR-Proficient+Ovarian+Cancers+at+ESMO+2026/26786816.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and <span value="ACORN:5021694850" idsrc="xmltag.org" >Hemispherian AS</span>, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that an abstract featuring pre-clinical data demonstrating strong synergy between GLIX1 and various PARP inhibitors in HR-proficient ovarian cancer cell lines has been accepted as an e-Poster at the 2026 European Society for Medical Oncology Annual Congress (ESMO 2026), taking place <chron>October http://www.streetinsider.com/PRNewswire/BioLineRx+and+Hemispherian+AS+to+Present+Data+Demonstrating+Strong+Synergy+of+GLIX1+with+PARP+Inhibitors+in+HR-Proficient+Ovarian+Cancers+at+ESMO+2026/26786816.html Mon, 20 Jul 2026 07:00:00 -0400 A.50216948 BLRX BLRX O.05892620 O.48070986 http://www.streetinsider.com/PRNewswire/BioLineRx+and+Hemispherian+AS+to+Present+Data+Demonstrating+Strong+Synergy+of+GLIX1+with+PARP+Inhibitors+in+HR-Proficient+Ovarian+Cancers+at+ESMO+2026/26786816.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and <span value="ACORN:5021694850" idsrc="xmltag.org" >Hemispherian AS</span>, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that an abstract featuring pre-clinical data demonstrating strong synergy between GLIX1 and various PARP inhibitors in HR-proficient ovarian cancer cell lines has been accepted as an e-Poster at the 2026 European Society for Medical Oncology Annual Congress (ESMO 2026), taking place <chron>October http://www.streetinsider.com/PRNewswire/BioLineRx+and+Hemispherian+AS+to+Present+Data+Demonstrating+Strong+Synergy+of+GLIX1+with+PARP+Inhibitors+in+HR-Proficient+Ovarian+Cancers+at+ESMO+2026/26786816.html Mon, 20 Jul 2026 07:00:00 -0400 A.50216948 BLRX BLRX O.05892620 O.48070986 http://www.streetinsider.com/PRNewswire/BioLineRx+and+Hemispherian+AS+to+Present+Data+Demonstrating+Strong+Synergy+of+GLIX1+with+PARP+Inhibitors+in+HR-Proficient+Ovarian+Cancers+at+ESMO+2026/26786816.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and <span value="ACORN:5021694850" idsrc="xmltag.org" >Hemispherian AS</span>, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that an abstract featuring pre-clinical data demonstrating strong synergy between GLIX1 and various PARP inhibitors in HR-proficient ovarian cancer cell lines has been accepted as an e-Poster at the 2026 European Society for Medical Oncology Annual Congress (ESMO 2026), taking place <chron>October http://www.streetinsider.com/PRNewswire/BioLineRx+and+Hemispherian+AS+to+Present+Data+Demonstrating+Strong+Synergy+of+GLIX1+with+PARP+Inhibitors+in+HR-Proficient+Ovarian+Cancers+at+ESMO+2026/26786816.html Mon, 20 Jul 2026 07:00:00 -0400 A.50216948 BLRX BLRX O.05892620 O.48070986 http://www.streetinsider.com/PRNewswire/BioLineRx+and+Hemispherian+AS+to+Present+Data+Demonstrating+Strong+Synergy+of+GLIX1+with+PARP+Inhibitors+in+HR-Proficient+Ovarian+Cancers+at+ESMO+2026/26786816.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and <span value="ACORN:5021694850" idsrc="xmltag.org" >Hemispherian AS</span>, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that an abstract featuring pre-clinical data demonstrating strong synergy between GLIX1 and various PARP inhibitors in HR-proficient ovarian cancer cell lines has been accepted as an e-Poster at the 2026 European Society for Medical Oncology Annual Congress (ESMO 2026), taking place <chron>October http://www.streetinsider.com/PRNewswire/BioLineRx+and+Hemispherian+AS+to+Present+Data+Demonstrating+Strong+Synergy+of+GLIX1+with+PARP+Inhibitors+in+HR-Proficient+Ovarian+Cancers+at+ESMO+2026/26786816.html Mon, 20 Jul 2026 07:00:00 -0400 A.50216948 BLRX BLRX O.05892620 O.48070986 http://www.streetinsider.com/PRNewswire/BioLineRx+and+Hemispherian+AS+to+Present+Data+Demonstrating+Strong+Synergy+of+GLIX1+with+PARP+Inhibitors+in+HR-Proficient+Ovarian+Cancers+at+ESMO+2026/26786816.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and <span value="ACORN:5021694850" idsrc="xmltag.org" >Hemispherian AS</span>, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that an abstract featuring pre-clinical data demonstrating strong synergy between GLIX1 and various PARP inhibitors in HR-proficient ovarian cancer cell lines has been accepted as an e-Poster at the 2026 European Society for Medical Oncology Annual Congress (ESMO 2026), taking place <chron>October http://www.streetinsider.com/PRNewswire/BioLineRx+and+Hemispherian+AS+to+Present+Data+Demonstrating+Strong+Synergy+of+GLIX1+with+PARP+Inhibitors+in+HR-Proficient+Ovarian+Cancers+at+ESMO+2026/26786816.html Mon, 20 Jul 2026 07:00:00 -0400 A.50216948 BLRX BLRX O.05892620 O.48070986 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BioLineRx+Ltd.++++++++++++For%3A+Jul+08/26744201.html si-local-file:///var/storage/secattach/20260708/26744201.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BioLineRx+Ltd.++++++++++++For%3A+Jul+08/26744201.html Wed, 08 Jul 2026 07:08:00 -0400 BLRX BLRX O.05892620 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BioLineRx+Ltd.++++++++++++For%3A+Jul+08/26744201.html si-local-file:///var/storage/secattach/20260708/26744201.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BioLineRx+Ltd.++++++++++++For%3A+Jul+08/26744201.html Wed, 08 Jul 2026 07:08:00 -0400 BLRX BLRX O.05892620 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BioLineRx+Ltd.++++++++++++For%3A+Jul+08/26744201.html si-local-file:///var/storage/secattach/20260708/26744201.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BioLineRx+Ltd.++++++++++++For%3A+Jul+08/26744201.html Wed, 08 Jul 2026 07:08:00 -0400 BLRX BLRX O.05892620 http://www.streetinsider.com/FDA/BioLineRx+and+Hemispherian+report+GLIX1+and+olaparib+synergy+in+ovarian+cancer/26744121.html <p>BioLineRx Ltd. (NASDAQ: BLRX, TASE: BLRX) and Hemispherian AS announced preclinical data showing a synergistic effect between GLIX1 and the PARP inhibitor olaparib in a patient-derived xenograft model of ovarian cancer.</p> <p>The study included six arms: cisplatin, GLIX1 monotherapy, olaparib monotherapy, low-dose GLIX1, a low-dose GLIX1/olaparib combination, and a control arm. The combination of low-dose GLIX1 and olaparib showed substantially better efficacy than either drug individually at its optimal dose and compared to the control arm. Tumor reduction in the combination arm was comparable to that seen with cisplatin, a standard chemotherapy benchmark.</p> <p>The results follow earlier in vitro findings in which http://www.streetinsider.com/FDA/BioLineRx+and+Hemispherian+report+GLIX1+and+olaparib+synergy+in+ovarian+cancer/26744121.html Wed, 08 Jul 2026 07:00:39 -0400 A.50216948 BLRX O.05892620 O.48070986 YP2 http://www.streetinsider.com/FDA/BioLineRx+and+Hemispherian+report+GLIX1+and+olaparib+synergy+in+ovarian+cancer/26744121.html <p>BioLineRx Ltd. (NASDAQ: BLRX, TASE: BLRX) and Hemispherian AS announced preclinical data showing a synergistic effect between GLIX1 and the PARP inhibitor olaparib in a patient-derived xenograft model of ovarian cancer.</p> <p>The study included six arms: cisplatin, GLIX1 monotherapy, olaparib monotherapy, low-dose GLIX1, a low-dose GLIX1/olaparib combination, and a control arm. The combination of low-dose GLIX1 and olaparib showed substantially better efficacy than either drug individually at its optimal dose and compared to the control arm. Tumor reduction in the combination arm was comparable to that seen with cisplatin, a standard chemotherapy benchmark.</p> <p>The results follow earlier in vitro findings in which http://www.streetinsider.com/FDA/BioLineRx+and+Hemispherian+report+GLIX1+and+olaparib+synergy+in+ovarian+cancer/26744121.html Wed, 08 Jul 2026 07:00:39 -0400 A.50216948 BLRX O.05892620 O.48070986 YP2 http://www.streetinsider.com/FDA/BioLineRx+and+Hemispherian+report+GLIX1+and+olaparib+synergy+in+ovarian+cancer/26744121.html <p>BioLineRx Ltd. (NASDAQ: BLRX, TASE: BLRX) and Hemispherian AS announced preclinical data showing a synergistic effect between GLIX1 and the PARP inhibitor olaparib in a patient-derived xenograft model of ovarian cancer.</p> <p>The study included six arms: cisplatin, GLIX1 monotherapy, olaparib monotherapy, low-dose GLIX1, a low-dose GLIX1/olaparib combination, and a control arm. The combination of low-dose GLIX1 and olaparib showed substantially better efficacy than either drug individually at its optimal dose and compared to the control arm. Tumor reduction in the combination arm was comparable to that seen with cisplatin, a standard chemotherapy benchmark.</p> <p>The results follow earlier in vitro findings in which http://www.streetinsider.com/FDA/BioLineRx+and+Hemispherian+report+GLIX1+and+olaparib+synergy+in+ovarian+cancer/26744121.html Wed, 08 Jul 2026 07:00:39 -0400 A.50216948 BLRX O.05892620 O.48070986 YP2 http://www.streetinsider.com/FDA/BioLineRx+and+Hemispherian+report+GLIX1+and+olaparib+synergy+in+ovarian+cancer/26744121.html <p>BioLineRx Ltd. (NASDAQ: BLRX, TASE: BLRX) and Hemispherian AS announced preclinical data showing a synergistic effect between GLIX1 and the PARP inhibitor olaparib in a patient-derived xenograft model of ovarian cancer.</p> <p>The study included six arms: cisplatin, GLIX1 monotherapy, olaparib monotherapy, low-dose GLIX1, a low-dose GLIX1/olaparib combination, and a control arm. The combination of low-dose GLIX1 and olaparib showed substantially better efficacy than either drug individually at its optimal dose and compared to the control arm. Tumor reduction in the combination arm was comparable to that seen with cisplatin, a standard chemotherapy benchmark.</p> <p>The results follow earlier in vitro findings in which http://www.streetinsider.com/FDA/BioLineRx+and+Hemispherian+report+GLIX1+and+olaparib+synergy+in+ovarian+cancer/26744121.html Wed, 08 Jul 2026 07:00:39 -0400 A.50216948 BLRX O.05892620 O.48070986 YP2 http://www.streetinsider.com/FDA/BioLineRx+and+Hemispherian+report+GLIX1+and+olaparib+synergy+in+ovarian+cancer/26744121.html <p>BioLineRx Ltd. (NASDAQ: BLRX, TASE: BLRX) and Hemispherian AS announced preclinical data showing a synergistic effect between GLIX1 and the PARP inhibitor olaparib in a patient-derived xenograft model of ovarian cancer.</p> <p>The study included six arms: cisplatin, GLIX1 monotherapy, olaparib monotherapy, low-dose GLIX1, a low-dose GLIX1/olaparib combination, and a control arm. The combination of low-dose GLIX1 and olaparib showed substantially better efficacy than either drug individually at its optimal dose and compared to the control arm. Tumor reduction in the combination arm was comparable to that seen with cisplatin, a standard chemotherapy benchmark.</p> <p>The results follow earlier in vitro findings in which http://www.streetinsider.com/FDA/BioLineRx+and+Hemispherian+report+GLIX1+and+olaparib+synergy+in+ovarian+cancer/26744121.html Wed, 08 Jul 2026 07:00:39 -0400 A.50216948 BLRX O.05892620 O.48070986 YP2 http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+Announce+New+Preclinical+Data+Demonstrating+Strong+Synergistic+Effect+between+GLIX1+and+PARP+Inhibitor+in+a+Patient-Derived+Ovarian+Cancer+Xenograft+Model/26744106.html <div class="xn-content"> <ul type="disc"><li><i>Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared to the control arm and compared to each drug individually at its optimal dose</i></li><li><i>GLIX1 in combination with olaparib also showed comparable efficacy to that seen with the chemotherapy drug cisplatin </i></li><li><i>Results reinforce synthetic lethality between GLIX1 and PARP inhibitors, indicating that GLIX1 can broaden the use of PARPi in ovarian cancer </i></li></ul><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 8, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+Announce+New+Preclinical+Data+Demonstrating+Strong+Synergistic+Effect+between+GLIX1+and+PARP+Inhibitor+in+a+Patient-Derived+Ovarian+Cancer+Xenograft+Model/26744106.html Wed, 08 Jul 2026 07:00:00 -0400 A.50216948 BLRX BLRX O.05892620 O.48070986 YP2 http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+Announce+New+Preclinical+Data+Demonstrating+Strong+Synergistic+Effect+between+GLIX1+and+PARP+Inhibitor+in+a+Patient-Derived+Ovarian+Cancer+Xenograft+Model/26744106.html <div class="xn-content"> <ul type="disc"><li><i>Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared to the control arm and compared to each drug individually at its optimal dose</i></li><li><i>GLIX1 in combination with olaparib also showed comparable efficacy to that seen with the chemotherapy drug cisplatin </i></li><li><i>Results reinforce synthetic lethality between GLIX1 and PARP inhibitors, indicating that GLIX1 can broaden the use of PARPi in ovarian cancer </i></li></ul><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 8, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+Announce+New+Preclinical+Data+Demonstrating+Strong+Synergistic+Effect+between+GLIX1+and+PARP+Inhibitor+in+a+Patient-Derived+Ovarian+Cancer+Xenograft+Model/26744106.html Wed, 08 Jul 2026 07:00:00 -0400 A.50216948 BLRX BLRX O.05892620 O.48070986 YP2 http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+Announce+New+Preclinical+Data+Demonstrating+Strong+Synergistic+Effect+between+GLIX1+and+PARP+Inhibitor+in+a+Patient-Derived+Ovarian+Cancer+Xenograft+Model/26744106.html <div class="xn-content"> <ul type="disc"><li><i>Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared to the control arm and compared to each drug individually at its optimal dose</i></li><li><i>GLIX1 in combination with olaparib also showed comparable efficacy to that seen with the chemotherapy drug cisplatin </i></li><li><i>Results reinforce synthetic lethality between GLIX1 and PARP inhibitors, indicating that GLIX1 can broaden the use of PARPi in ovarian cancer </i></li></ul><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 8, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+Announce+New+Preclinical+Data+Demonstrating+Strong+Synergistic+Effect+between+GLIX1+and+PARP+Inhibitor+in+a+Patient-Derived+Ovarian+Cancer+Xenograft+Model/26744106.html Wed, 08 Jul 2026 07:00:00 -0400 A.50216948 BLRX BLRX O.05892620 O.48070986 YP2 http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+Announce+New+Preclinical+Data+Demonstrating+Strong+Synergistic+Effect+between+GLIX1+and+PARP+Inhibitor+in+a+Patient-Derived+Ovarian+Cancer+Xenograft+Model/26744106.html <div class="xn-content"> <ul type="disc"><li><i>Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared to the control arm and compared to each drug individually at its optimal dose</i></li><li><i>GLIX1 in combination with olaparib also showed comparable efficacy to that seen with the chemotherapy drug cisplatin </i></li><li><i>Results reinforce synthetic lethality between GLIX1 and PARP inhibitors, indicating that GLIX1 can broaden the use of PARPi in ovarian cancer </i></li></ul><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 8, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+Announce+New+Preclinical+Data+Demonstrating+Strong+Synergistic+Effect+between+GLIX1+and+PARP+Inhibitor+in+a+Patient-Derived+Ovarian+Cancer+Xenograft+Model/26744106.html Wed, 08 Jul 2026 07:00:00 -0400 A.50216948 BLRX BLRX O.05892620 O.48070986 YP2 http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+Announce+New+Preclinical+Data+Demonstrating+Strong+Synergistic+Effect+between+GLIX1+and+PARP+Inhibitor+in+a+Patient-Derived+Ovarian+Cancer+Xenograft+Model/26744106.html <div class="xn-content"> <ul type="disc"><li><i>Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared to the control arm and compared to each drug individually at its optimal dose</i></li><li><i>GLIX1 in combination with olaparib also showed comparable efficacy to that seen with the chemotherapy drug cisplatin </i></li><li><i>Results reinforce synthetic lethality between GLIX1 and PARP inhibitors, indicating that GLIX1 can broaden the use of PARPi in ovarian cancer </i></li></ul><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 8, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+Announce+New+Preclinical+Data+Demonstrating+Strong+Synergistic+Effect+between+GLIX1+and+PARP+Inhibitor+in+a+Patient-Derived+Ovarian+Cancer+Xenograft+Model/26744106.html Wed, 08 Jul 2026 07:00:00 -0400 A.50216948 BLRX BLRX O.05892620 O.48070986 YP2 http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+Announce+New+Preclinical+Data+Demonstrating+Strong+Synergistic+Effect+between+GLIX1+and+PARP+Inhibitor+in+a+Patient-Derived+Ovarian+Cancer+Xenograft+Model/26744106.html <div class="xn-content"> <ul type="disc"><li><i>Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared to the control arm and compared to each drug individually at its optimal dose</i></li><li><i>GLIX1 in combination with olaparib also showed comparable efficacy to that seen with the chemotherapy drug cisplatin </i></li><li><i>Results reinforce synthetic lethality between GLIX1 and PARP inhibitors, indicating that GLIX1 can broaden the use of PARPi in ovarian cancer </i></li></ul><p><span class="legendSpanClass"><location value="LU/il..telavv" idsrc="xmltag.org" >TEL AVIV, Israel</location> and <location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>July 8, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:BLRX" idsrc="xmltag.org" >BioLineRx Ltd.</span> (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage http://www.streetinsider.com/Press+Releases/BioLineRx+and+Hemispherian+Announce+New+Preclinical+Data+Demonstrating+Strong+Synergistic+Effect+between+GLIX1+and+PARP+Inhibitor+in+a+Patient-Derived+Ovarian+Cancer+Xenograft+Model/26744106.html Wed, 08 Jul 2026 07:00:00 -0400 A.50216948 BLRX BLRX O.05892620 O.48070986 YP2